Boehringer provides update on iclepertin Phase III program in schizophrenia
January 16, 2025 10:05 ET
|
Boehringer Ingelheim Limited
Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints were...
Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
January 16, 2025 08:00 ET
|
Emergent BioSolutions
Africa CDC’s support for the MOSA has enabled the enrollment of the first patients at Mbandaka Hospital in Equateur Province, Democratic Republic of Congo.
Ivy Brain Tumor Center Expands Global Phase 3 Gliofocus Study to the EU and Additional U.S. States
January 15, 2025 09:00 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The Gliofocus Study is now open in Paris and Madrid. The global Gliofocus network includes 68 EU medical centers. In the United States, The...
BellaSeno Successfully Completes Two Clinical Trials with Novel, Resorbable Breast Implants
January 14, 2025 04:00 ET
|
AKAMPION
One-year follow-up data confirm favorable safety profile of BellaSeno´s scaffolds compared to silicone implantsCompany plans expansion to primary breast augmentation and lumpectomy Leipzig, Germany/...
Prodeon Medical Announces Enrollment Completion for Expander-2 Pivotal Trial
January 13, 2025 08:00 ET
|
Prodeon Medical
Prodeon Medical completes patient enrollment for the Expander-2 Trial, a study evaluating the Urocross Expander System for LUTS due to BPH.
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
January 09, 2025 11:35 ET
|
Abivax
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment Phase 3 ABTECT Trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) reaches 1,003 of 1,224...
RQ Bio welcomes positive CHMP opinion on Kavigale for prevention of COVID-19 in immunocompromised individuals
January 09, 2025 05:00 ET
|
RQ Biotechnology
RQ Bio welcomes positive CHMP opinion on Kavigale for prevention of COVID-19 in immunocompromised individuals
ViGeneron Announces FDA Rare Pediatric Disease Designation for VG901 and DSMB Approval to Advance Dose Escalation in Phase 1b Retinitis Pigmentosa Trial
January 08, 2025 08:00 ET
|
ViGeneron GmbH
VG901 is the first-in-class and only clinical-stage therapy designed to deliver the functional CNGA1 gene intravitreally (IVT) to target retinal photoreceptor cells in patients with retinitis...
tiakis Biotech AG Receives Positive Scientific Advice from the U.S. FDA for Planned Phase II Trial of Tiprelestat
January 08, 2025 04:00 ET
|
AKAMPION
- tiakis and Stanford University are preparing for a Phase II in Pulmonary Arterial Hypertension (PAH) Kiel, Germany, January 8, 2025 – tiakis Biotech AG, a clinical-stage biopharmaceutical company...
CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in India
January 06, 2025 07:00 ET
|
CYTOMED THERAPEUTICS LIMITED
SINGAPORE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing...